GLP-1 Receptor Agonists: Mechanisms of Action and Class Overview

The glucagon-like peptide-1 receptor agonist class has undergone a transformation in clinical relevance over the past decade — from second-line glycaemic agents to first-in-class therapies for obesity-related cardiovascular risk reduction. Understanding their pharmacology is no longer optional for metabolic clinicians.

Incretin Physiology: The Biological Foundation

GLP-1 is a 30-amino-acid peptide secreted by L-cells in the distal small intestine and colon in response to nutrient ingestion. Endogenous GLP-1 exerts its effects through a G-protein-coupled receptor (GLP-1R) expressed widely across tissues: pancreatic beta cells, the central nervous system, cardiovascular tissue, kidneys, and the gastrointestinal tract itself. The native peptide has a plasma half-life of roughly 2 minutes, cleaved rapidly by dipeptidyl peptidase-4 (DPP-4) — a limitation that pharmaceutical development has overcome through structural modification.

Activation of the GLP-1R on pancreatic beta cells stimulates glucose-dependent insulin secretion: insulin is released only when ambient glucose is elevated, which is why this class carries an intrinsically low risk of hypoglycaemia when used as monotherapy. Simultaneously, GLP-1R activation suppresses glucagon secretion from alpha cells, slows gastric emptying, and — critically for weight management — signals satiety through vagal afferents and direct hypothalamic pathways.

Structural Modifications That Define the Class

First-generation GLP-1 receptor agonists were engineered to resist DPP-4 cleavage. Exenatide, derived from the Gila monster peptide exendin-4, shares approximately 53% sequence homology with human GLP-1 but is not a DPP-4 substrate. Liraglutide achieved extended activity through fatty acid acylation, enabling albumin binding and a half-life of 13 hours — long enough for once-daily dosing.

Semaglutide took this further: a C-18 fatty diacid chain attached via a hydrophilic linker to the peptide backbone produces an albumin-binding affinity that yields a half-life of approximately 165–184 hours, underpinning weekly subcutaneous or daily oral administration. The oral formulation co-administers semaglutide with sodium N-[8-(2-hydroxybenzoyl) aminocaprylate] (SNAC), which transiently increases gastric pH and facilitates transcellular absorption through the gastric epithelium — a genuinely novel delivery mechanism for a peptide drug.

Central Nervous System Effects and Weight Reduction

The weight-loss magnitude seen with high-dose GLP-1 agonists — particularly semaglutide 2.4 mg weekly and tirzepatide 15 mg weekly — cannot be explained solely by gastric slowing. Neuroimaging and preclinical studies point toward direct action on the arcuate nucleus and nucleus of the solitary tract, modulating the hypothalamic circuits governing appetite, reward-driven feeding, and energy expenditure. Rodent models show GLP-1R agonist-induced reduction in the motivational salience of high-calorie foods — an observation now under active investigation in human neuroimaging cohorts.

The clinical data are striking. In the STEP 1 trial, once-weekly subcutaneous semaglutide 2.4 mg produced a mean weight reduction of 14.9% from baseline over 68 weeks in adults with obesity without diabetes — compared with 2.4% with placebo. Roughly one-third of participants achieved ≥20% weight loss. These are numbers previously associated only with bariatric surgery.

Cardiovascular and Renal Effects: Beyond Glycaemia

GLP-1R expression in cardiomyocytes and vascular endothelium has prompted sustained investigation of direct cardioprotective effects. The LEADER trial (liraglutide), SUSTAIN-6 (semaglutide), and most recently the SELECT trial (semaglutide 2.4 mg) have each demonstrated statistically significant reductions in three-point MACE — a composite of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death. SELECT is particularly notable because it enrolled patients with established cardiovascular disease but without diabetes, isolating the cardiovascular effect from glycaemic improvement.

Renal protective effects — reduced progression to macroalbuminuria, slowed eGFR decline — have been observed in several trials, likely mediated through haemodynamic, anti-inflammatory, and direct tubular mechanisms.

Tolerability Profile and Practical Considerations

Gastrointestinal adverse effects — nausea, vomiting, diarrhoea, constipation — are the class's most frequent tolerability issue, occurring in 30–50% of patients to some degree. These effects are generally dose-dependent and attenuate over weeks to months with gradual dose escalation protocols. The risk of acute pancreatitis has been flagged since early post-marketing surveillance; current evidence suggests a modest elevation in risk, though causality has not been definitively established. Prescribers should exercise caution in patients with a history of pancreatitis or medullary thyroid carcinoma — the latter based on rodent data showing C-cell hyperplasia, a signal not yet replicated in human surveillance.

Muscle mass loss accompanying rapid weight reduction is an emerging clinical concern, prompting interest in combining GLP-1 therapies with structured resistance training protocols.

Approved Agents: Comparative Summary

Source: Published RCT primary endpoint data. Figures represent mean placebo-adjusted weight loss unless otherwise stated. SC = subcutaneous injection.